European Respiratory Journal

Papers
(The TQCC of European Respiratory Journal is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis1993
Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study924
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19580
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge546
Pathogenesis of COVID-19 from a cell biology perspective541
Cardiovascular comorbidity and its impact on patients with COVID-19453
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension411
A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis355
The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19337
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline327
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset311
ERS/ATS technical standard on interpretive strategies for routine lung function tests296
Association between age and clinical characteristics and outcomes of COVID-19277
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial272
No association of COVID-19 transmission with temperature or UV radiation in Chinese cities271
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study267
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?265
ERS statement on chronic thromboembolic pulmonary hypertension263
Pulmonary embolism in patients with COVID-19 pneumonia263
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients249
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial249
COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force244
ERS clinical practice guidelines on treatment of sarcoidosis238
COVID-19 and pneumothorax: a multicentre retrospective case series219
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19212
COVID-19 and COPD210
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China209
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes207
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases196
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective195
Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation195
Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia182
High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion182
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study181
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19178
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary173
Universal use of face masks for success against COVID-19: evidence and implications for prevention policies170
Trends in worldwide asthma prevalence163
Pathogenesis of COVID-19-induced ARDS: implications for an ageing population158
Will children reveal their secret? The coronavirus dilemma152
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome148
The potential impact of COVID-19-related disruption on tuberculosis burden145
Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study143
The impact of COVID-19 on patients with asthma142
The natural history of progressive fibrosing interstitial lung diseases140
Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication140
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline139
Patient-reported outcome measures after COVID-19: a prospective cohort study137
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry136
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection136
Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China135
COVID-19 and smoking: is nicotine the hidden link?132
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors132
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma131
Thrombosis and COVID-19 pneumonia: the clot thickens!129
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study126
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update126
Mepolizumab effectiveness and identification of super-responders in severe asthma122
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue121
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation119
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers117
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life115
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review114
Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study110
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection107
Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study107
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension107
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure106
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase105
Methotrexate and rheumatoid arthritis associated interstitial lung disease104
Current smoking is not associated with COVID-19104
Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital101
Endothelial cells in the pathogenesis of pulmonary arterial hypertension101
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab101
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis101
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry100
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies98
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years98
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)95
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis95
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study92
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial92
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics90
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis90
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences90
Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up90
Novel coronavirus infection in newborn babies aged <28 days in China89
Social stigma in the time of coronavirus disease 201986
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients86
Effect of asthma and asthma medication on the prognosis of patients with COVID-1986
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator85
Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS84
Between inflammation and thrombosis: endothelial cells in COVID-1983
The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China83
Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public82
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study82
On tuberculosis and COVID-19 co-infection82
Managing the supportive care needs of those affected by COVID-1981
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure79
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline79
Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy: from ward to trenches79
European Respiratory Society guidelines for the diagnosis of asthma in adults79
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation78
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis78
European Respiratory Society statement on long COVID follow-up78
Potential of regulatory T-cell-based therapies in the management of severe COVID-1977
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health76
The importance of interventional timing in the bleomycin model of pulmonary fibrosis76
COVID-19, tuberculosis and poverty: preventing a perfect storm76
Treatment options in type-2 low asthma74
Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow74
Epidemic and pandemic viral infections: impact on tuberculosis and the lung74
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry73
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial72
Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA)72
European Respiratory Society statement on thoracic ultrasound70
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena69
Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis68
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study68
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors67
COVID-19: guidance on palliative care from a European Respiratory Society international task force66
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation66
Targeting transforming growth factor-β receptors in pulmonary hypertension65
COVID-19 and pulmonary rehabilitation: preparing for phase three65
Clinical application of an intelligent oropharyngeal swab robot: implication for the COVID-19 pandemic64
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry64
COVID-19 and nicotine as a mediator of ACE-264
Phenotyping long COVID62
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects62
Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients62
Strategies for the prevention and management of coronavirus disease 201961
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital60
“You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise59
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)59
Interstitial lung disease increases susceptibility to and severity of COVID-1958
EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke58
Effect of aerobic exercise training on asthma in adults: a systematic review and meta-analysis58
Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis57
Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial57
Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease56
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study56
Asthma remission: what is it and how can it be achieved?56
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study56
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms55
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme55
Asthma and COVID-19 risk: a systematic review and meta-analysis54
Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs54
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry54
Tuberculosis and COVID-19 co-infection: description of the global cohort54
COVID-19 and the nicotinic cholinergic system54
Metabolomic analyses reveal new stage-specific features of COVID-1953
Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs53
Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis52
Sleep-related breathing disorders and pulmonary hypertension52
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry52
Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?52
Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism52
Risk factors for viral RNA shedding in COVID-19 patients52
Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study52
Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation52
Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia51
Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: open source hardware description, performance and feasibility testing51
Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor50
Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection49
High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU48
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study48
Topological data analysis reveals genotype–phenotype relationships in primary ciliary dyskinesia48
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk48
Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?48
The physiological basis of pulmonary arterial hypertension48
Vascular permeability in the fibrotic lung48
Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection47
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy47
Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation47
Smoking, ACE-2 and COVID-19: ongoing controversies47
A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis47
European Respiratory Society statement on sleep apnoea, sleepiness and driving risk46
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial46
Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study46
Epigenetics and pulmonary diseases in the horizon of precision medicine: a review46
COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry46
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody46
Estimates of the ongoing need for social distancing and control measures post-“lockdown” from trajectories of COVID-19 cases and mortality46
Air pollution and the development of asthma from birth until young adulthood45
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease45
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry45
The perils of premature phenotyping in COVID-19: a call for caution45
Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature45
Comorbid insomnia and sleep apnoea is associated with all-cause mortality45
Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB44
Short-term outcomes of COVID-19 and risk factors for progression44
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis44
Elevated pulmonary vascular resistance predicts mortality in COPD patients43
Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)43
Emergence of bedaquiline resistance in a high tuberculosis burden country43
Clinical and CT features of early stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China43
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension43
More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China43
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?43
Environmental fungal sensitisation associates with poorer clinical outcomes in COPD43
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial43
Asthma management in low and middle income countries: case for change42
High-resolution computed tomography features of 17 cases of coronavirus disease 2019 in Sichuan province, China42
Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort42
TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signalling42
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma42
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support42
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial41
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis41
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry41
Go slow to go fast: a plea for sustained scientific rigour in air pollution research during the COVID-19 pandemic41
Steroid use in elderly critically ill COVID-19 patients41
Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial40
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients40
Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study40
Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting40
When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases40
Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients40
Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma39
COVID-19 and vaping: risk for increased susceptibility to SARS-CoV-2 infection?39
World Health Organization treatment outcome definitions for tuberculosis: 2021 update39
Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?39
Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study39
Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure38
Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients38
A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD38
Lung function trajectory in progressive fibrosing interstitial lung disease38
A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension38
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis37
Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge37
Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells37
Arterial hypertension and the risk of severity and mortality of COVID-1937
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort37
The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study37
Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study37
Risk stratification in pulmonary arterial hypertension using Bayesian analysis37
Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approaches37
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-1937
The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes37
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients37
A randomised trial of high-flow nasal cannula in infants with moderate bronchiolitis37
Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK36
Blood eosinophils predict inhaled fluticasone response in bronchiectasis36
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma36
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension36
Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells36
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization36
The (in)significance of TB and COVID-19 co-infection36
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society36
Celebrating World Tuberculosis Day at the time of COVID-1936
0.045252084732056